Insmed Incorporated announced on October 5, 2026, that Sara Bonstein, the company's Chief Financial Officer, will separate from the company effective October 30, 2026. Ms. Bonstein will remain in her role through the reporting of the third-quarter 2026 financial results and will participate in the subsequent earnings call on October 29, 2026.
The company stated that the transition is not related to any disagreement regarding accounting practices, financial statements, internal controls, or operations. Ms. Bonstein will receive the benefits outlined in her Amended and Restated Employment Agreement dated April 1, 2022. Insmed has initiated a search to identify her successor and has engaged a leading executive search firm for the process.
In a statement regarding the transition, Will Lewis, Chair and Chief Executive Officer, noted that Ms. Bonstein oversaw the company’s finance organization during a period in which Insmed raised more than $4.2 billion in capital. He added that the company is positioned to reach cash flow positivity next year with a clear path toward sustained growth.
Separately, Insmed reaffirmed its full-year 2026 financial guidance. The company projects revenue for BRINSUPRI (brensocatib) to be between $1.25 billion and $1.40 billion. Revenue for ARIKAYCE (amikacin liposome inhalation suspension) is expected to fall within the range of $450 million to $470 million.
Insmed also announced that it will release its third-quarter 2026 financial results on Thursday, October 29, 2026. Management will host a conference call at 8:00 a.m. ET to discuss the results and provide a business update.
